Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.

Introduction: KRAS and EGFR ectodomain-acquired mutations in patients with metastatic colorectal cancer (mCRC) have been correlated with acquired resistance to anti-EGFR monoclonal antibodies (mAbs). We investigated the frequency, co-occurrence, and distribution of acquired KRAS and EGFR mutations in patients with mCRC refractory to anti-EGFR mAbs using circulating tumor DNA (ctDNA).

Patients And Methods: Sixty-two post-treatment plasma and 20 matching pretreatment archival tissue samples from KRAS (wt) mCRC patients refractory to anti-EGFR mAbs were evaluated by high-sensitivity emulsion polymerase chain reaction for KRAS codon 12, 13, 61, and 146 and EGFR 492 mutations.

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.

Objective: A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to investigate clinical and molecular predictors of outcome.

Methods: 59 patients with advanced HCC received 10 mg/kg i.v.

Maturation of evoked potentials and visual preference in 6-45-day-old infants: effects of check size, visual acuity, and refractive error.

Visual evoked potentials (VEPs) and the percentage time fixated (PTF) were investigated in response to checkerboard light flashes in 10 human infaed as a function of the size of check in the evoking stimulus (diffuse light, 11, 22, 45, 90 and 180 min of arc), the refractive lens strength the checkerboards were viewed through (-6 to +6 diopters), and the age of the infants (6-26 or 27-45 days). Check size significantly influenced VEP amplitude in infants as young as 6 days. The 11' checks evoked greater responses that diffuse light suggesting a visual acuity of better than 20/220.